Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
Open Access
- 7 August 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 1595
Abstract
Objective: Targeting immune checkpoints, such as PD-1, represents a promising approach for cancer immunotherapy, achieving long-term disease remission rates in numerous types of cancer. T cell immunoglobulin and ITIM domain (TIGIT) is a checkpoint receptor associated with the antitumor roles of NK and T cells. Notably, the blockade of TIGIT has been revealed as a potential promising approach in cancer immunotherapy. However, the therapeutic potential of blocking TIGIT in myelodysplastic syndrome (MDS) remains unclear and further research is required to reveal their role. Methods: Fresh peripheral blood (PB) and bone marrow (BM) were obtained from patients with MDS and healthy donors (HDs) at the Tianjin Medical University General Hospital between January 21 2018 and March 22 2019. The present study investigated the expression levels of TIGIT on NK and T cells using flow cytometry (FCM) and PCR. In addition, other checkpoint receptors, such as CD226 and PD-1, were also investigated. To determine the mechanisms of antitumor immunity, the functions of NK and T cells expressing TIGIT were determined. Results: TIGIT was found to be highly expressed on NK and T cells of the PB, where it was involved in disease progression and the immune escape of MDS. The high expression levels of TIGIT were associated with decreased NK and T cell function, and significantly lower secretions of activation factors, such as CD107a, IFN-γ and TNF-α. Notably, blocking TIGIT enhanced the antitumor effects of NK and T cells. Conclusion: The results of the present study suggested that targeting TIGIT alone or in combination with PD-1 may be a promising anticancer therapeutic strategy in MDS.Keywords
Funding Information
- Innovative Research Group Project of the National Natural Science Foundation of China
- Tianjin Industrial and Information Technology Commission
- Natural Science Foundation of Tianjin Municipality
This publication has 39 references indexed in Scilit:
- Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell TransplantationBlood Cancer Journal, 2019
- Optimising management of deferasirox therapy for patients with transfusion‐dependent thalassaemia and lower‐risk myelodysplastic syndromesEuropean Journal of Haematology, 2018
- Discriminating myelodysplastic syndrome and other myeloid malignancies from non-clonal disorders by multiparametric analysis of automated cell dataClinica Chimica Acta, 2018
- Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?Cancer, 2017
- Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2015
- Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasmsInternational Journal of Hematology, 2015
- Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemiaAmerican Journal of Hematology, 2013
- Myelodysplastic syndromes: What do hospitalists need to know?Journal of Hospital Medicine, 2013
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010Journal of the National Comprehensive Cancer Network, 2011